GKOS
Glaukos Corporation
GKOS has lower modeled downside risk, despite its lower overall score.
OSCR
Oscar Health, Inc.
OSCR has the edge over GKOS overall, supported by stronger fundamentals.
GKOS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Healthy | |
| Weak |
GKOS's revenue and cash flow are currently healthy, but its profitability and balance sheet are weak.
OSCR Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Healthy | |
| Strong | |
| Strong |
OSCR's revenue, profitability, cash flow and balance sheet are all currently healthy.
GKOS PE Valuation
GKOS has no meaningful PE right now: it lost money over the past year. If it returns to profit as analysts expect, today's price would be 170x next year's earnings.
OSCR PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $31.94 | — |
| Current | 13x | $31.94 | — |
| Cheap | 21x | $52.73 | +65% |
| Fair | 35x | $87.23 | +173% |
| Expensive | 130x | $322 | +907% |
Historical ranges are pointers, not guarantees.
OSCR's PE is 13x, but its earnings don't support one, so it isn't a reliable read right now.
GKOS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Returning to profit | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Low |
Analysts expect GKOS to return to profit, with revenue growing. However, they disagree widely on these estimates.
OSCR Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for OSCR, with profitability improving.
GKOS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $1.44 | — |
| Q3 2026 | -$2.96 | -$1.46 |
| Q2 2026 | -$3.27 | -$1.66 |
| Q1 2026 | -$3.30 | -$1.03 |
| Q4 2025 | -$3.28 | -$0.51 |
| Q3 2025 | -$1.50 | +$1.46 |
| Q2 2025 | -$1.61 | +$1.59 |
| Q1 2025 | -$2.27 | +$0.61 |
| Q4 2024 | -$2.77 | +$0.01 |
GKOS lost $2.96 per share over the past year, a bigger loss than the year before.
OSCR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.61 | +5.6% |
| Q3 2026 | $2.47 | +$3.47 |
| Q2 2026 | $1.45 | +$2.14 |
| Q1 2026 | -$0.54 | -235% |
| Q4 2025 | -$1.69 | -1790% |
| Q3 2025 | -$1.00 | -$0.92 |
| Q2 2025 | -$0.69 | -$0.54 |
| Q1 2025 | $0.40 | +$0.82 |
| Q4 2024 | $0.10 | +$1.32 |
OSCR has the edge over GKOS on earnings quality, reporting a profit while its opponent remains loss making.
GKOS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $211M | +58% |
| Q2 2026 | $185.6M | +50% |
| Q1 2026 | $150.6M | +41% |
| Q4 2025 | $143.1M | +36% |
| Q3 2025 | $133.5M | +38% |
| Q2 2025 | $124.1M | +30% |
| Q1 2025 | $106.7M | +25% |
| Q4 2024 | $105.5M | +28% |
GKOS's revenue has grown year over year for 15 quarters in a row: $211M last quarter, up 58% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 0.4% | +13 points |
| Q2 2026 | -9.3% | +9 points |
| Q1 2026 | -13% | +6.2 points |
| Q4 2025 | -98% | -71 points |
| Q3 2025 | -12% | +13 points |
| Q2 2025 | -18% | +13 points |
| Q1 2025 | -19% | +26 points |
| Q4 2024 | -27% | +20 points |
GKOS's operating margin was 0.4% last quarter, up 13 points from the same quarter a year ago.
OSCR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $5.1B | +72% |
| Q2 2026 | $4.9B | +70% |
| Q1 2026 | $4.6B | +53% |
| Q4 2025 | $2.8B | +17% |
| Q3 2025 | $3B | +23% |
| Q2 2025 | $2.9B | +29% |
| Q1 2025 | $3B | +42% |
| Q4 2024 | $2.4B | +67% |
OSCR has the edge over GKOS on sales, with stronger typical year-over-year growth.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 3.5% | +7.8 points |
| Q2 2026 | 8% | +16 points |
| Q1 2026 | 15% | +5.4 points |
| Q4 2025 | -12% | -5.7 points |
| Q3 2025 | -4.3% | -2.3 points |
| Q2 2025 | -8.1% | -11 points |
| Q1 2025 | 9.8% | +1.1 points |
| Q4 2024 | -6.2% | +4 points |
OSCR has the edge over GKOS on profitability, with a higher operating margin.
GKOS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $36.5M | +$48.2M |
| Q2 2026 | $12.1M | +108% |
| Q1 2026 | -$16.5M | +$4M |
| Q4 2025 | $3.9M | +$5.2M |
| Q3 2025 | -$11.7M | -$689K |
| Q2 2025 | $5.8M | +$26.3M |
| Q1 2025 | -$20.5M | +$14.4M |
| Q4 2024 | -$1.2M | +$13.7M |
GKOS has the edge over OSCR on cash flow, with more consistent year-over-year improvement.
OSCR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.2B | -$238.2M |
| Q2 2026 | $2.1B | +316% |
| Q1 2026 | $2.6B | +200% |
| Q4 2025 | $662.8M | +95% |
| Q3 2025 | -$973.7M | -$466M |
| Q2 2025 | $499.8M | +2.1% |
| Q1 2025 | $869.5M | +38% |
| Q4 2024 | $340M | +17% |
OSCR usually generates cash, though not every quarter: the latest was −$1.2B, but it generated $4.1B over the past year.
GKOS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +4% | +2.4M shares |
| 1 year | +6.6% | +3.8M shares |
| 3 years | +26% | +12.5M shares |
| 5 years | +24% | +11.9M shares |
| Available history | +49% | +20.1M shares |
GKOS has the edge over OSCR on shareholder dilution, with a more favorable share count trend.
OSCR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.9% | +13M shares |
| 1 year | +34% | +87.2M shares |
| 3 years | +55% | +123M shares |
| 5 years | +66% | +138M shares |
| Available history | +71% | +143M shares |
OSCR has 346M diluted shares, up 34% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
GKOS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2022 | 9.4x | High |
GKOS's net debt is about 9.3 years of its operating earnings (EBITDA).
OSCR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -4.2x | Net Cash |
| Q2 2026 | -5.5x | Net Cash |
| Q1 2026 | -110.0x | Net Cash |
| Q1 2025 | -9.7x | Net Cash |
| Q4 2024 | -13.7x | Net Cash |
| Q3 2024 | -10.1x | Net Cash |
| Q2 2024 | -24.0x | Net Cash |
| Q1 2024 | -217.7x | Net Cash |
OSCR has more cash than debt.
GKOS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 74.8 | Overbought |
| Stochastic | 84.2 | Overbought |
GKOS's weekly RSI is 75 (overbought) and its Stochastic is 84 (overbought).
OSCR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 58.7 | Neutral |
| Stochastic | 44.9 | Neutral |
OSCR's weekly RSI is 59 (neutral) and its Stochastic is 45 (neutral).
GKOS PE vs Healthcare Sector
GKOS has no meaningful PE right now: it lost money over the past year.
OSCR PE vs Healthcare Sector
| Metric | OSCR | Sector median | Relative |
|---|---|---|---|
| PE | 13x | 26x | 50% below |
| PE % | 3 | 35 | 32 pts below |
OSCR is trading at 13x earnings, a 50% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
GKOS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $192.0 | 28% above |
| 20 week MA | $177.6 | 39% above |
| 50 week MA | $142.0 | 73% above |
| 100 week MA | $123.5 | 99% above |
| 200 week MA | $106.0 | 132% above |
GKOS is in an uptrend: it's above all five of its weekly moving averages, and 132% above its 200-week average.
OSCR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $31.2 | 2.3% above |
| 20 week MA | $31.1 | 2.8% above |
| 50 week MA | $22.9 | 39% above |
| 100 week MA | $19.3 | 65% above |
| 200 week MA | $15.5 | 106% above |
OSCR is in an uptrend: it's above all five of its weekly moving averages, and 106% above its 200-week average.
GKOS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $55.0 | $74.0 | +35% |
| 2021 | $74.0 | $46.8 | -37% |
| 2022 | $46.8 | $42.6 | -8.9% |
| 2023 | $42.6 | $79.5 | +86% |
| 2024 | $79.5 | $151.2 | +90% |
| 2025 | $151.2 | $116.2 | -23% |
| 2026 YTD | $116.2 | $246.0 | +112% |
GKOS is up 112% so far in 2026, after finishing lower in three of the previous six years.
OSCR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $31.0 | $8.02 | -74% |
| 2022 | $8.02 | $2.21 | -72% |
| 2023 | $2.21 | $9.15 | +314% |
| 2024 | $9.15 | $13.8 | +51% |
| 2025 | $13.8 | $14.9 | +8% |
| 2026 YTD | $14.9 | $31.9 | +114% |
OSCR has the edge over GKOS on returns for 2026, with the stronger performance.